Filing Details
- Accession Number:
- 0000947871-18-000156
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-15 16:57:01
- Reporting Period:
- 2018-02-13
- Accepted Time:
- 2018-02-15 16:57:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1583648 | Pieris Pharmaceuticals Inc. | PIRS | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1055951 | Orbimed Advisors Llc | 601 Lexington Avenue, 54Th Floor New York NY 10022 | No | No | Yes | No | |
| 1432241 | Orbimed Capital Gp Iii Llc | 601 Lexington Avenue, 54Th Floor New York NY 10022 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-02-13 | 6,057 | $4.68 | 5,506,787 | No | 4 | M | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2018-02-13 | 58 | $4.68 | 49,328 | No | 4 | M | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2018-02-13 | 1,765 | $5.08 | 5,508,552 | No | 4 | M | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2018-02-13 | 17 | $5.08 | 49,345 | No | 4 | M | Indirect | See Footnotes |
| Common Stock | Disposition | 2018-02-13 | 7,822 | $8.98 | 5,500,730 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2018-02-13 | 75 | $8.98 | 49,270 | No | 4 | S | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Indirect | See Footnotes |
| No | 4 | M | Indirect | See Footnotes |
| No | 4 | M | Indirect | See Footnotes |
| No | 4 | M | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-02-13 | 6,057 | $0.00 | 6,057 | $4.68 |
| Common Stock | Stock Option (right to buy) | Disposition | 2018-02-13 | 58 | $0.00 | 58 | $4.68 |
| Common Stock | Stock Option (right to buy) | Disposition | 2018-02-13 | 1,765 | $0.00 | 1,765 | $5.08 |
| Common Stock | Stock Option (right to buy) | Disposition | 2018-02-13 | 17 | $0.00 | 17 | $5.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-02-15 | No | 4 | M | Indirect | |
| 0 | 2018-02-15 | No | 4 | M | Indirect | |
| 0 | 2018-02-15 | No | 4 | M | Indirect | |
| 0 | 2018-02-15 | No | 4 | M | Indirect |
Footnotes
- The stock options were included in an award to Chau Khuong, an employee of the Reporting Persons, made on October 25, 2017 for services as a director of the Issuer. The award included stock options relating to a total of 6,115 shares of the Issuer's Common Stock and was vested and exercisable on October 25, 2017. Mr. Khuong is no longer a director of the Issuer.
- The stock options were included in an award to Chau Khuong, an employee of the Reporting Persons, made on January 25, 2018 for services as a director of the Issuer. The award included stock options relating to a total of 1,782 shares of the Issuer's Common Stock and was vested and exercisable on January 25, 2018. Mr. Khuong is no longer a director of the Issuer.
- These Shares are held of record by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP III. By virtue of such relationships, GP III and Advisors may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI III.
- These Shares are held of record by OrbiMed Associates III, LP ("Associates III"). Advisors is the general partner of Associates III. By virtue of such relationships, Advisors may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by Associates III.
- Samuel D. Isaly, who was included as a Reporting Person on previous reports under Section 16 of the Exchange Act filed by GP III and Advisors, is no longer subject to Section 16 with respect to securities of the Issuer.
- This report on Form 4 is jointly filed by GP III and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Billionaire Hedge Funds
